| PyloriMed |
Phase 2 ready for H Pylori eradication, GERD
H Pylori strongly linked to chronic active gastritis, peptic ulcer, atrophic gastritis, MALT lymphoma and gastric cancer . ?
Eradication limited by antibiotic resistance, suboptimal acid suppression and pill burden leading to poor compliance. ?
* Pylori Med’s novel CMA-PPI H. pylori eradication regimen combines long-duration pro-omeprazole with amoxicillin?
* Phase 2 ready with established CMC methods and more than sufficient intermediate for Phase 2?
Good market potential with 3 million prescriptions in US for PPI plus antibiotic in 2016. ?
Huge Upside in nighttime acid breakthru GERD
| 新型CMA-PPI制劑
幽門螺旋桿菌根除綜合解決方案。
目前研發(fā)進(jìn)度已經(jīng)到臨床二期。
研究表明，幽門螺桿菌與慢性活動(dòng)性胃炎、消化性潰瘍、萎縮性胃炎、MALT淋巴瘤和胃癌密切相關(guān)。
但幽門螺桿菌的根除受限于抗生素耐藥性，抑制胃酸不理想和藥物負(fù)擔(dān)等問題，效果不理想。
我們的新產(chǎn)品針對(duì)上述痛點(diǎn)，結(jié)合了長(zhǎng)效的奧美拉唑和阿莫西林，為幽門螺桿菌的治療提出了新型的治療解決方案。
產(chǎn)品優(yōu)勢(shì)：
*已通過成熟的CMC方法，并提供了足夠的中間體，為臨床2期做好準(zhǔn)備。
*良好的市場(chǎng)潛力，2016年在美國(guó)有300萬張PPI加抗生素處方。
*對(duì)于GRED，夜間酸突破方面能帶來巨大的好處。
|
| ABCENTRA |
Phase 2 Ab to oxLDL
Orticumab - Anti-inflammatory monoclonal antibodies targeting oxidized low-density lipoprotein (oxLDL). ?
Preparing for Phase II?
*260 patients have been treated with excellent safety profile through 3 clinical trials. ?
*Possible indications include: ?atherosclerosis, psoriasis.
| 泰凌醫(yī)藥(01011.HK)發(fā)布公告，于2022年6月21日，被許可方Green-Life Technology (Hong Kong) CompanyLimited（公司全資附屬公司）與許可方Abcentra LLC訂立許可及合作協(xié)議，據(jù)此，許可方有條件同意不可撤銷地授予被許可方許可，即于中國(guó)、香港、澳門、臺(tái)灣、新加坡、馬來西亞及泰國(guó)等地區(qū)將該技術(shù)商業(yè)化的獨(dú)家永久許可。
|
| APTITUDE VISION |
VEGF/ang2 bispecific aptamer for ophthalmology
Standard of care anti-VEGF has limited efficacy and frequent injections
* ?Aptitude's aptamer has added efficacy from ang2?
* ?And 10x greater VEGF potency and 100x greater ang2 potency than Roche Faricimab
* ?And much longer duration
These combine to mean MUCH longer time over minimal effective concentration = LESS FREQUENT DOSING
|
眼科用VEGF / ang2雙特異性抗體
抗VEGF的護(hù)理標(biāo)準(zhǔn)療效有限且經(jīng)常注射
* Aptitude的適體增加了ang2的功效
*與Roche Faricimab相比，VEGF效能高10倍，ang2效能高100倍
*持續(xù)時(shí)間更長(zhǎng)
這些結(jié)合在一起意味著在最小有效濃度下需要更長(zhǎng)的時(shí)間=更少的劑量
|
| BridGene Biosciences |
With a platform with covalent inhibitors to 5000 targets, BridGene can collaborate to?
* ?identify a hit for a hard to drug-like hit target and provide information on selectivity to enable a rapid creation of a lead candidate
* ?identify the targets of phenotypic screens
Two ?covalent inhibitors programs ready for partnering
FGFR4 inhibitor for cancer: ?
* ?small molecule with oral bioavailability,?
* ?efficacy and regression in HCC and Rhabdomyosarcoma models
* ?great selectivity
* ?inhibition of gatekeeper mutations
GMPS inhibitor for lupus and other autoimmune disorders:?
Novel immunosupressant
GMPS is downstream of IMPDH in purine synthesis where approved MPA (MMF) immunosuppressant acts?
* nM potency
* suppression of T cell activation and T cell growth
* In vivo effects
|
帶有共價(jià)抑制劑的平臺(tái)借助具有針對(duì)5000個(gè)靶標(biāo)的共價(jià)抑制劑的平臺(tái)，BridGene可以與
*確定難以被藥物針對(duì)的目標(biāo)，并提供有關(guān)選擇性的信息，以快速創(chuàng)建潛在候選化合物
*確定表型篩選的目標(biāo)
兩個(gè)共價(jià)抑制劑計(jì)劃準(zhǔn)備合作
1. FGFR4癌癥抑制劑：
*具有口服生物利用度的小分子，
*在HCC和橫紋肌肉瘤模型中的療效和消退
*極大的選擇性 *抑制網(wǎng)守突變
2. GMPS狼瘡和其他自身免疫性疾病的抑制劑：新型免疫抑制劑
GMPS在嘌呤合成中IMPDH的下游，其中批準(zhǔn)的MPA（MMF）免疫抑制劑起作用
* nM有效劑量， 抑制T細(xì)胞活化和T細(xì)胞生長(zhǎng)*體內(nèi)作用
|
| GLYCONEX |
?A humanized IgG antibody GNX102 for cancer in Phase 1 in US and Taiwan.
* ?Targeted to biantennary LeY to target many cancers with higher selectivity versus normal cells.
* ?GNX102 showed great anti-tumor efficacy in human tumor xenograft models.
* ?Pilot toxicology studies showed that GNX102 was well tolerated in tested rats, dogs, and Cynomolgus monkeys.
* ?GNX102 showed superior safety profile in GLP tox studies in rat and Cynomolgus monkeys.
|
一種在美國(guó)和臺(tái)灣用于1期臨床治療癌癥的人源化IgG抗體GNX102。
*針對(duì)雙天線LeY，以比正常細(xì)胞更高的選擇性靶向許多癌癥。
* GNX102在人類腫瘤異種移植模型中顯示出出色的抗腫瘤功效。
*初步毒理學(xué)研究表明，GNX102在測(cè)試的大鼠，狗和食蟹猴中具有良好的耐受性。
* GNX102在大鼠和食蟹猴的GLP毒理研究中顯示出優(yōu)異的安全性。
|
| LOKI THERAPEUTICS |
Breakthrough cancer immunotherapy with antigens of childhood vaccination?
* ?Activates and redirects pre-existing memory T cells created during childhood tetanus vaccination to solid tumors and metastases
* ?Attenuated Listeria infects tumor homing MDSC to deliver the antigens to the tumors
* ?Unlike many approaches where converting naive T cells to memory T cells is hard in older patients
* ?Antigens very immunogenic and not subject to tumor mutagenesis
|
采用兒童接種抗原的突破性癌癥免疫療法
*激活并重定向在兒童破傷風(fēng)疫苗接種過程中產(chǎn)生的先前存在的記憶T細(xì)胞，使其轉(zhuǎn)移至實(shí)體瘤和轉(zhuǎn)移灶
*減毒李斯特菌感染腫瘤歸巢MDSC，將抗原傳遞給腫瘤
*與許多在老年患者中很難將幼稚T細(xì)胞轉(zhuǎn)化為記憶T細(xì)胞的方法不同
*抗原具有很高的免疫原性，不會(huì)引起腫瘤誘變
|
| EXTEND BIO |
Peptide therapeutics with extended duration and subcutaneous bioavailability
* ?Long-acting grelin derivative for cancer cachexia - a single dose reverses cachexia in animal models
* Long-acting PTH for hypoparathyroidism
|
具有更長(zhǎng)持續(xù)時(shí)間和皮下生物利用度的多肽治療劑
*長(zhǎng)效Grelin衍生物可治療癌癥惡病質(zhì)-單劑量可逆轉(zhuǎn)動(dòng)物模型中的惡病質(zhì)
*長(zhǎng)效甲狀旁腺激素可治療甲狀旁腺功能低下
|
| Sound Biologics |
Pair of Abs from a single cell to be a single drug entity, allowing different isotypes and stoichiometries, for rapid product creation
* ?In Phase 1: ??PSB205: ?PD1 and CTLA4 Abs from a single cell designed to have rapid clearance of the CTLA4 for optimal efficacy
* ?Multiple IO candidates including PD1/x, ?CD20/CD37 pair, Her2/Her2 pair
* ?Also seeking partnerships on platform
|
一對(duì)來自單個(gè)細(xì)胞的抗體成為一個(gè)單一的藥物實(shí)體，允許不同的同種型和化學(xué)計(jì)量比，以快速創(chuàng)建產(chǎn)品
*臨床1期：PSB205：來自單個(gè)細(xì)胞的PD1和CTLA4抗體設(shè)計(jì)用于快速清除CTLA4，以實(shí)現(xiàn)最佳功效
*多個(gè)腫瘤免疫候選項(xiàng)目，包括PD1 / x，CD20 / CD37對(duì)，Her2 / Her2
*此平臺(tái)尋求合作伙伴
|
| Glyconex |
well characterized biosimilar to denosumab for osteoporosis and bone metastases from multiple myeloma
* 200L scale with cell line
* Great comparability and stability
|
與地諾單抗相似的生物仿制藥，用于治療多發(fā)性骨髓瘤的骨質(zhì)疏松和骨轉(zhuǎn)移
* 200L規(guī)模細(xì)胞株
*出色的可比性和穩(wěn)定性
|